Daily Cannabis News Brief for 7/28/2026

Below is a breakdown of the top cannabis news stories for July 28, 2026, with each title linking to a full article. The Marijuana Herald publishes a new edition every weekday at around 3 p.m. Pacific Time. This, and future editions, can be found by clicking here.

Federal Data Shows More Americans Use Marijuana Daily or Almost Daily Than Cigarettes or Alcohol

An estimated 21.4 million Americans used marijuana on at least 20 of the previous 30 days in 2025, exceeding the 19.9 million who smoked cigarettes daily and the 17.2 million who consumed alcohol with similar frequency. The federal data shows the number of people using marijuana daily or almost daily has increased by nearly 4 million since 2021, while daily cigarette smoking has continued to decline.

 

California Dispensary Becomes First in State Approved to Launch RFID-Powered Self-Checkout

A Sacramento dispensary has become the first licensed marijuana retailer in California approved by state regulators to operate an RFID-powered self-checkout system. The technology, now available at Perfect Union Northside, can identify multiple products simultaneously and communicates with the dispensary’s point-of-sale platform and California’s track-and-trace system. The system is designed to reduce checkout times while providing real-time inventory data, loss prevention tools and simplified inventory counts.

 

Researchers Call for State-Led Medical Marijuana Research Centers Following Federal Rescheduling

Researchers writing in Clinical Therapeutics say states with established medical marijuana programs should create independent research centers following federal rescheduling. The proposed centers could centralize patient and product data, standardize the documentation of outcomes and adverse events and generate real-world evidence on marijuana’s safety and therapeutic effects. The authors say the centers should receive sustained funding while remaining independent from political and regulatory influence.

 

CBD-Dominant Cannabis Extract Reduced Symptoms and Restored Skin Barrier Proteins in Atopic Dermatitis Model, Study Finds

A CBD-dominant cannabis extract reduced inflammation, improved skin lesions and restored proteins involved in maintaining the skin barrier in a mouse model of atopic dermatitis, according to a study published in Nutrients. Both tested doses reduced redness, dryness, swelling and skin damage, while the higher dose produced results comparable to the corticosteroid dexamethasone in several measurements. Researchers said human clinical trials are needed to confirm the findings.

 

Texas Ban on Delta-8 and Other Hemp-Derived THC Products Takes Effect Friday

Texas retailers must stop selling delta-8 THC and several other hemp-derived intoxicating cannabinoids beginning Friday, July 31. The restrictions follow the reinstatement of controlled-substance definitions originally adopted by state health officials in 2021 but blocked by a court injunction until this year. The definitions are expected to prohibit products containing delta-8 THC, delta-10 THC, THCP and similar cannabinoids while preserving the exemption for hemp containing no more than 0.3% delta-9 THC.

 

The 6 States Most Likely to Become the 25th to Legalize Recreational Marijuana

With recreational marijuana now legal in 24 states, Hawaii, Pennsylvania, New Hampshire, Florida, South Dakota and North Dakota appear best positioned to become the 25th. Hawaii and Pennsylvania have increasingly viable legislative paths, while Florida and the Dakotas have demonstrated substantial support at the ballot box. Elections taking place in November could significantly alter the outlook for several of the states heading into 2027 and 2028.

 

University of Mississippi Cannabis Research Center Launches CBD Sleep Study

The National Center for Cannabis Research and Education at the University of Mississippi is partnering with Southern Sky Brands on a clinical study examining CBD’s effects on sleep duration, sleep quality and overall wellness among adults. The study will assess both safety and effectiveness, although details regarding enrollment, dosage, methodology and timing have not been announced.